Cardiotoxicity and pro-inflammatory effects of the immune checkpoint inhibitor Pembrolizumab associated to Trastuzumab

MLA

M. De Laurentiis, et al. Cardiotoxicity and Pro-Inflammatory Effects of the Immune Checkpoint Inhibitor Pembrolizumab Associated to Trastuzumab. Jan. 2019. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....93cf0325727fcc210c44ac62a6d93928&authtype=sso&custid=ns315887.

APA

M. De Laurentiis, C. De Lorenzo, Margherita Passariello, C. Coppola, M. Scherillo, Vincenzo Quagliariello, D.W. Rea, Rosario Vincenz Iaffaioli, Nicola Maurea, Antonio Barbieri, Maria Chiara Monti, Paolo A. Ascierto, & G. Botti. (2019). Cardiotoxicity and pro-inflammatory effects of the immune checkpoint inhibitor Pembrolizumab associated to Trastuzumab.

Chicago

M. De Laurentiis, C. De Lorenzo, Margherita Passariello, C. Coppola, M. Scherillo, Vincenzo Quagliariello, D.W. Rea, et al. 2019. “Cardiotoxicity and Pro-Inflammatory Effects of the Immune Checkpoint Inhibitor Pembrolizumab Associated to Trastuzumab,” January. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....93cf0325727fcc210c44ac62a6d93928&authtype=sso&custid=ns315887.